The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
Study Details
Study Description
Brief Summary
To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
-
Patients may receive oral acyclovir and may continue prophylactic treatment for PCP, fungal infection, MAC and toxoplasmosis.
-
Topical treatment and intralesional chemotherapy will be allowed for lesions which will not be used as indicator or biopsy lesions.
Concurrent Treatment:
Allowed:
Localized radiotherapy will be allowed for lesions which will not be used as indicator or biopsy lesions.
Patients must have:
-
Documentation of a positive ELISA test for HIV with a confirmatory test.
-
Biopsy proven, cutaneous or oropharyngeal Kaposi's sarcoma.
-
Vital signs, physical examination and laboratory assessments that exhibit no evidence of an acute illness.
-
Patients must agree to report all current medications to the primary investigator and obtain prior permission to use them when feasible.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
-
Evidence of pulmonary Kaposi's sarcoma.
-
Positive urine screen for recreational drugs.
-
Current participation in another antiviral research study.
-
Investigator anticipates poor patient compliance with the protocol.
-
Patient has any condition that, in the investigator's opinion, may obscure the proper observation of the safety or activity of ritonavir.
Concurrent Medication:
Excluded:
-
Antiretroviral therapy.
-
Protease inhibitor therapy.
-
Antiviral agent (e.g., oral ganciclovir or Foscarnet) or prophylactic medication for an AIDS defining illness which the patient cannot be removed from.
-
Chemotherapy for Kaposi's sarcoma.
-
Treatment with any medications that may interact with ritonavir.
Concurrent Treatment:
Excluded:
Radiotherapy for Kaposi's sarcoma.
Patients with any of the following prior conditions are excluded:
-
History of psychiatric illness which is currently medically significant.
-
History of pancreatitis.
Prior Medication:
Excluded:
-
All antiretroviral therapy within 2 weeks prior to the start of the treatment phase of the study.
-
Systemic chemotherapy of interferon within 30 days prior to study entry.
-
Previous treatment with a protease inhibitor.
Risk Behavior:
Excluded:
Active substance abuse.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Prince Henry's Hosp / Med Oncology | Sydney | Australia | ||
2 | Saint Vincent's Hosp Med Centre | Sydney | Australia |
Sponsors and Collaborators
- Abbott
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- 245C
- M95-320